Gallus Announces Completion of $5 Million Process Development Expansion
News Feb 07, 2014
Gallus BioPharmaceuticals, LLC (Gallus) has completed a second expansion of its Process Development (PD) facility at its headquarters in St. Louis, Missouri.
This expansion provides additional laboratory space and instrumentation to support Gallus’ growth and commitment to leading pharma and biotech clients in the development of new biotherapeutics.
Mark R. Bamforth, Gallus’ President and CEO, stated “Following the acquisition of the Laureate Biopharma business last September, Gallus is now supporting 5 of the top 15 pharmaceutical companies and a growing number of emerging and mid-sized biotechs in bringing new molecules to the clinic. This additional investment increases Gallus’ capacity to serve our clients’ needs with our team of over 70 Process Development scientists. We’ve designed the new integrated PD labs to facilitate collaborative and efficient development and tech transfer of processes. The design allows our Process Development team flexibility in adjusting for project specific configurations as needed.”
The expansion includes the addition of the ambr™ System from TAP Biosystems, a high throughput system designed for microscale clone and media selection and bioreactor process optimization. This addition is in response to the rapidly growing need for optimizing the yields and purity of complex biotherapeutic molecules.
“The ambr™ high-throughput mini-bioreactor system allows Gallus to develop robust, high-producing cell culture processes for our clients while reducing time lines and meeting regulatory expectations”, stated Matt Caple, Director of Cell Culture Development at Gallus.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE